Infliximab, azathioprine, or combination therapy for Crohn's disease.
暂无分享,去创建一个
P. Rutgeerts | G. D'Haens | A. Kornbluth | C. J. van der Woude | W. Sandborn | W. Reinisch | J. Colombel | D. Rachmilewitz | G. Mantzaris | S. Lichtiger | J. Colombel | R. Diamond | D. Broussard | K. Tang | William J. Sandborn | D. Broussard | C. Janneke van der Woude | Jean Frédéric Colombel | Gerassimos J. Mantzaris | Robert H. Diamond | Delma L. Broussard | Kezhen L. Tang
[1] C. O'Morain,et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.
[2] H. Arrighi,et al. Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease , 2009, The American Journal of Gastroenterology.
[3] W. Sandborn,et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials , 2009, Alimentary pharmacology & therapeutics.
[4] S. Hanauer,et al. Management of Crohn's Disease in Adults , 2001, The American Journal of Gastroenterology.
[5] S. Schreiber,et al. A Multicenter, Randomized, Double-Blind Trial of Everolimus Versus Azathioprine and Placebo to Maintain Steroid-Induced Remission in Patients With Moderate-to-Severe Active Crohn's Disease , 2008, The American Journal of Gastroenterology.
[6] D. Margolis,et al. Immunosuppressant Medications and Mortality in Inflammatory Bowel Disease , 2008, The American Journal of Gastroenterology.
[7] P. Rutgeerts,et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. , 2008, Gastroenterology.
[8] L. Peyrin-Biroulet,et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[9] Mark Avigan,et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. , 2007, Journal of pediatric gastroenterology and nutrition.
[10] W. Sandborn,et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[11] J. Mary,et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. , 2006, Gastroenterology.
[12] W. Tremaine,et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.
[13] A. Forbes,et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management , 2006, Gut.
[14] M. Bala,et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] M. Neurath,et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. , 2003, The Journal of clinical investigation.
[16] M. Neurath,et al. CD 28-dependent Rac 1 activation is the molecular target of azathioprine in primary human CD 4 + T lymphocytes , 2003 .
[17] F. Carbonnel,et al. Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.
[18] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[19] P. Rutgeerts,et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. , 2002, Gastroenterology.
[20] S. Deventer,et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease , 2002, Gut.
[21] A. Zinsmeister,et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.
[22] J. Markowitz,et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. , 2000, Gastroenterology.
[23] S. Targan,et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.
[24] S. Targan,et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. , 1999, Gastroenterology.
[25] H. McLeod,et al. Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine , 1998, Annals of Internal Medicine.
[26] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .
[27] G. Greenberg,et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. , 1996, Gastroenterology.
[28] M. Gerig,et al. A controlled double blind study of azathioprine in the management of Crohn's disease. , 1995, Gut.
[29] G. Fick,et al. Azathioprine and 6-Mercaptopurine in Crohn Disease , 1995, Annals of Internal Medicine.
[30] G. Fick,et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. , 1995, Annals of internal medicine.
[31] G. Greenberg,et al. Oral Budesonide for Active Crohn's Disease , 1994 .
[32] J. Rochon,et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.
[33] B. Pasternack,et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. , 1980, The New England journal of medicine.
[34] R. Summers,et al. National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.
[35] F Kern,et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.